CD43 antibody
Quick Overview for CD43 antibody (ABIN5707565)
Target
See all CD43 (SPN) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- Purified
-
Purity
- Protein A affinity chromatography
-
Immunogen
- Recombinant human protein was used as the immunogen for the recombinant CD43 antibody.
-
Isotype
- IgG kappa
-
-
-
-
Application Notes
-
Optimal dilution of the recombinant CD43 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1) -
Restrictions
- For Research Use only
-
-
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the recombinant CD43 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- CD43 (SPN) (Sialophorin (SPN))
-
Alternative Name
- CD43
-
Background
- It recognizes a cell surface glycoprotein of 95/115/135 kDa (depending upon the extent of glycosylation), identified as CD43. 70-90 % of T-cell lymphomas and from 22-37 % of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.
-
Pathways
- Regulation of Leukocyte Mediated Immunity
Target
-